Provided by Tiger Trade Technology Pte. Ltd.

Galmed Pharmaceuticals

3.92
-0.1990-4.83%
Post-market: 4.300.3800+9.69%18:10 EDT
Volume:12.02K
Turnover:47.53K
Market Cap:4.08M
PE:-0.24
High:4.06
Open:4.05
Low:3.90
Close:4.12
52wk High:13.20
52wk Low:3.29
Shares:1.04M
Float Shares:1.01M
Volume Ratio:1.03
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-16.1401
EPS(LYR):-19.1292
ROE:-72.12%
ROA:-33.45%
PB:0.29
PE(LYR):-0.20

Loading ...

Galmed Pharmaceuticals Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
2 hours ago

Galmed Pharmaceuticals Shareholders Approve All Proposals at September 3 AGM

TIPRANKS
·
4 hours ago

Galmed Pharmaceuticals Holds Annual Shareholder Meeting

Reuters
·
7 hours ago

Galmed Pharmaceuticals Posts Higher R&D Spend and Shrinking Cash in Q2 2026

TIPRANKS
·
Yesterday

Galmed Pharmaceuticals Adjourns Shareholder Meeting for Lack of Quorum

TIPRANKS
·
Yesterday

Galmed Pharmaceuticals Effects 1-for-8 Reverse Stock Split

Reuters
·
Yesterday

Galmed Adjourns Annual Shareholder Meeting to Sept. 3 After Lack of Quorum

Reuters
·
Yesterday

Galmed Pharmaceuticals Ltd Expected to Post a Loss of $3.12 a Share - Earnings Preview

Reuters
·
Aug 24

Galmed Amends AGM Proxy Materials Ahead of Sept. 2 Shareholder Vote

Reuters
·
Aug 20

Colospan completes feasibility study of new assesment platform

TIPRANKS
·
Aug 19

Galmed Says Colospan Intraoperative Colon Tissue Assessment Study Meets Feasibility Goal in First-in-Human Trial

Reuters
·
Aug 19

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

THOMSON REUTERS
·
Aug 19

Galmed trading halted, news pending

TIPRANKS
·
Aug 19

NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Reuters
·
Aug 19

Galmed reports results from study of a combination of Aramchol and Xtandi

TIPRANKS
·
Aug 17

Galmed Says Aramchol-Xtandi Combo Lifts Prostate Cancer Cell Death 3-4 Fold in Preclinical Study

Reuters
·
Aug 17

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (Xtandi®) Alone in Prostate Cancer Models

THOMSON REUTERS
·
Aug 17

Galmed Pharmaceuticals to Execute 1-for-8 Reverse Share Split Aug. 19, 2026

Reuters
·
Aug 15

Galmed Pharmaceuticals Wins Nasdaq Extension to Regain $1 Bid Price Compliance

TIPRANKS
·
Aug 01

Galmed Pharmaceuticals: as a Result of Termination, All Rights to Licensed Technology Will Revert to Yissum

THOMSON REUTERS
·
Jul 30